BAY 3605349 / Bayer - LARVOL DELTA

Translational pharmacokinetic/pharmacodynamic (PK/PD) modeling for VVD-130037, a novel, first-in-class covalent small molecule Kelch-like ECH-associated protein 1 (KEAP1) activator (AACR 2025) - "A translational PK/PD model is developed for VVD-130037; supporting efficacious doses during clinical development."

PK/PD data • Oncology • KEAP1

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=280 | Recruiting | Sponsor: Vividion Therapeutics, Inc. | N=80 ➔ 280

Enrollment change • Oncology • Solid Tumor

Discovery of VVD-130037: A first-in-class covalent allosteric KEAP1 activator for the treatment of NRF2-activated cancers (ACS-Fall 2024) - "We will describe the identification of these molecules and the elucidation of their mechanism of action and associated structural biology. Optimization of both the intrinsic efficacy for KEAP1 activation/NRF2 degradation and pharmacokinetic properties resulted in a lead molecule, VVD-130037, which is currently being evaluated in patients with advanced solid tumors."

Oncology • Solid Tumor • KEAP1